

Ref: FOI/GS/ID 8021

Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone, Kent ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

www.mtw.nhs.uk

22 February 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to biologic and biosimilar products within Rheumatology.

You asked: All questions are shown as received by the Trust. We are analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]

- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

Trust response:

Under Section 21 of the Act we are not required to provide information in response to a request if the information is already reasonably accessible to you. The information you requested is available from the trust website using the following link/s: https://www.mtw.nhs.uk/freedom-of-information/recent-foiresponses/ the link should take you to the Data to Support FOI FAQ's page where you need to click on the Pharmacy dropdown. If the document does not open please copy and paste the link into your browser.

Alternatively, from our website home page, click the Freedom of Information Tab, then the Data to Support FOI FAQ's tab and then the Pharmacy dropdown at the bottom of the page where you will find all the information.

This information is updated on a regular basis and is exempt under Section 22 of the Act.